ReviewSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[Application of Domestic Robotic Surgical Systems in Gynecologic Surgery].
Review in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, domestically developed surgical robot systems have rapidly progressed from laboratory research to clinical applications in gynecological surgery, demonstrating multi-dimensional advancement and accelerated development. Systems such as Toumai, Jingfeng, Surui, Haishanyi, and MicroHand S have been progressively deployed in both routine and complex procedures, including surgeries for uterine fibroids, ovarian cysts, and gynecologic malignancies such as cervical, endometrial, and ovarian cancers. These systems have established a technology pathway characterized by independent research and development, clinical validation, and expanded indications. They generally offer advantages such as 3D high-definition imaging, highly flexible robotic arms, and precise dissection capabilities, enabling refined operations in the deep pelvis and supporting multi-angle tissue dissection with enhanced visualization, stability, and trauma control. Some systems, including the Surui and Jingfeng SP series, have also demonstrated strong adaptability in single-port and natural orifice (e.g., v-NOTES) approaches. Additionally, 5G-based telesurgery has been preliminarily explored, promoting regional medical collaboration and technology dissemination in underserved areas. Although most domestic systems remain in early-stage clinical adoption with limited large-scale comparative studies and long-term follow-up data, initial outcomes are promising in terms of intraoperative safety, postoperative recovery, and patient experience. However, compared to the Da Vinci system, further evidence is needed regarding their precision in highly complex tumor resections, management of intraoperative complications, and long-term oncological outcomes. Therefore, large-sample, multi-center, prospective studies with long-term follow-up are urgently needed to validate their efficacy and safety and to promote standardized application in gynecological oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.